Zanolimumab: Difference between revisions

Zanolimumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD4
Clinical data
ATC code	none;
Identifiers
CAS Number	652153-01-0 ;
ChemSpider	none;
UNII	HG3L8885M0;
KEGG	D06356 ;
Chemical and physical data
Molar mass	147 kg/mol
	(what is this?) (verify)

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 06:29, 31 December 2023

Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.^[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,^[2] cutaneous and peripheral T-cell lymphoma.^[3]^[4] Development of the drug was ultimately discontinued with termination of all trials.^[5]

References[edit]

^ Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.
^ "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[Mestel_2008-1] Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.

[2] "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.

[4] Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov

[5] "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.

[1]

[2]

[3]

[4]

[5]

@@ Line 1: / Line 1: @@
+{{short description|Human monoclonal antibody}}
 {{Drugbox
 | Verifiedfields = changed
+| Watchedfields = changed
 | verifiedrevid = 470635574
 | image =
+<!-- Monoclonal antibody data -->
-<!--Monoclonal antibody data-->
 | type = mab
 | mab_type = mab
 | source = u
 | target = [[CD4]]
+<!-- Clinical data -->
-<!--Clinical data-->
 | tradename =
 | pregnancy_AU =
@@ Line 21: / Line 21: @@
 | legal_status =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
-<!--Pharmacokinetic data-->
 | bioavailability =
 | protein_bound =
@@ Line 28: / Line 27: @@
 | elimination_half-life =
 | excretion =
+<!-- Identifiers -->
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-<!--Identifiers-->
+| ChemSpiderID = none
-| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-| ChemSpiderID = NA
 | CAS_number_Ref = {{cascite|changed|??}}
 | CAS_number = 652153-01-0
@@ Line 43: / Line 41: @@
 | KEGG_Ref = {{keggcite|correct|kegg}}
 | KEGG = D06356
+<!-- Chemical data -->
-<!--Chemical data-->
 | chemical_formula =
-| molecular_weight = 147 [[kDa]]
+| molecular_weight = 147
+| molecular_weight_comment = kg/mol
 }}
-'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>http://www.tenxbiopharma.com/development.shtml</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref>
+'''Zanolimumab''' is an investigational [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]].<ref name="Mestel_2008">{{cite journal | vauthors = Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C | title = Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome | journal = Expert Opinion on Biological Therapy | volume = 8 | issue = 12 | pages = 1929–39 | date = December 2008 | pmid = 18990079 | doi = 10.1517/14712590802528696 | s2cid = 58115371 }}</ref> It was developed with the goal of treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=TenX BioPharma |access-date=August 20, 2010 |url-status=dead |archive-url=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archive-date=April 11, 2010 }}</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> Development of the drug was ultimately discontinued with termination of all trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|access-date=6 November 2011}}</ref>
 == References ==